Key Highlights

  • Procter & Gamble agreed to acquire science-backed wellness brand Thorne for 3.8 billion dollars in cash from private equity firm L Catterton.
  • The deal represents a return of more than 3 billion dollars for L Catterton, which took Thorne private in a 680 million dollar transaction in 2023.
  • Thorne was reportedly the subject of a competing bid from consumer health company Haleon earlier this year, though P&G's chief executive declined to confirm whether a bidding war occurred.
  • The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions and regulatory approvals.

A Deepening Push Into Premium Health and Wellness

Procter & Gamble (NYSE:PG) has entered a definitive agreement to acquire Thorne, a science-backed health and wellness brand, for 3.8 billion dollars in cash from L Catterton, the private equity firm's Flagship Fund. The acquisition extends P&G's existing supplements portfolio, which currently includes New Chapter, Metamucil and Align Probiotic, adding a premium, practitioner-trusted brand as the company seeks greater exposure to a health and wellness sector that has been expanding faster than its traditional household staples business.

Thorne's chief executive said the company sought a partner capable of helping it continue advancing toward becoming the world's most trusted personalized health brand, while P&G's health care division leadership described the deal as an important step in strengthening the company's position within premium wellness alongside its existing portfolio. The move comes as P&G recently forecast slower annual sales growth for the year ahead, even as its beauty and wellness division posted strong results driven by consumer willingness to spend on discretionary self-care products.

A Strong Return for Thorne's Prior Private Equity Owner

L Catterton, which describes itself as the largest global consumer-focused investment firm, took Thorne private in October 2023 in a transaction valued at 680 million dollars, betting on what it viewed as an enduring shift in consumer behavior toward proactive, clinically backed health products. The 3.8 billion dollar sale price to P&G represents a return exceeding 3 billion dollars for L Catterton, reflecting substantial value creation over the less than three-year holding period.

During its ownership, L Catterton said it helped recruit new leadership, expanded Thorne's marketing and commercial capabilities, increased investment in scientific research and development, and built out technology infrastructure including a proprietary AI-powered wellness advisor. A managing partner at the firm characterized the investment as reflecting the firm's core strategy of identifying enduring consumer behavior shifts and partnering with category-leading brands, while a partner at the firm expressed confidence that P&G was well positioned to build on the growth momentum established during L Catterton's ownership period.

Deal Reflects Broader Consolidation Trend in the Supplements Sector

The acquisition places P&G among several major multinational consumer goods companies competing for position within the vitamins, minerals and supplements sector. Rival Unilever (NYSE:UL) announced its own acquisition of nutritional supplements brand Gruns in April for an undisclosed amount, while Nestle has been conducting a strategic review of its lower-growth, lower-margin supplement brands, suggesting an industry-wide reassessment of how large consumer goods companies want to participate in this category.

Thorne itself had reportedly drawn interest from consumer health company Haleon earlier this year, according to sources familiar with the matter, though P&G's chief executive declined to confirm whether a competitive bidding process took place before the deal was finalized. Thorne, founded in 1984 and briefly public before L Catterton's 2023 take-private transaction, had been forecasting annual sales of 290 million dollars in 2023 and was reported earlier this year to be on pace to reach 650 million dollars in sales this year, indicating substantial revenue growth during the period of private ownership.

Conclusion

P&G's acquisition of Thorne reflects a broader strategic push among major consumer goods companies to capture growing consumer demand for premium, science-backed wellness products, arriving alongside comparable moves from rivals Unilever and Nestle within the same sector. The deal delivers a substantial return for L Catterton while positioning P&G to leverage Thorne's practitioner relationships and scientific credibility within its existing health portfolio. Whether the acquisition meaningfully accelerates P&G's broader wellness strategy is likely to depend on how effectively the company integrates Thorne's brand positioning and technology capabilities alongside its established supplement offerings.